Table 5.
Summary of improvements in HRQoL measures in response to etanercept by treatment group
| Adjusted mean change from baseline | Week 12 | Week 24 | ||
|---|---|---|---|---|
| QW/QW n = 86 | BIW/QW n = 84 | QW/QW n = 86 | BIW/QW n = 84 | |
| DLQI, mean (SEM) | −8.4† (0.5) | −10.8† (0.5) | −9.5† (0.6) | −11.0† (0.6) |
| EQ-5D, mean (SEM) | 0.2 (0.0) | 0.3* (0.0) | 0.2* (0.0) | 0.3* (0.0) |
| WPAI: % activity impairment due to problem, mean (SEM) | −19.1† (2.3) | −25.1† (2.3) | −22.1† (2.2) | −27.3† (2.3) |
| WPAI: % impairment while working due to problem, mean (SEM) | −7.5 (2.5)† | −16.3 (2.6)*† | −11.8 (2.0)† | −18.8 (2.0)*† |
| WPAI: % overall work impairment due to problem, mean (SEM) | −7.8 (3.3)† | −15.1 (3.2)† | −13.5 (2.8)† | −16.3 (2.8)† |
| WPAI: % work time missed due to problem, mean (SEM) | −3.4 (2.6)† | 0.4 (2.5)† | −6.1 (2.3)† | 0.6 (2.3)*† |
| Total FACIT, mean (SEM) | 3.2† (0.7) | 4.5† (0.7) | 4.5† (0.8) | 4.3† (0.8) |
Missing data were imputed using the last observation carried forward method
*p < 0.05 between treatment groups at the same time point. † p < 0.01 from baseline within treatment group
BIW twice weekly, DLQI Dermatology Life Quality Index, EQ-5D EuroQoL 5 Dimension, FACIT Functional Activity in Chronic Therapy, HRQoL health-related quality of life, QW once weekly, SEM standard error of the mean, WPAI Work Productivity and Activity Impairment scale